BioMarin Pharmaceuticals, Inc. (BMRN)

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

COMPANY ADDRESS
105 Digital Drive
Novato, CA 94949
United States

COMPANY PHONE
415-506-6700

COMPANY WEBSITE



Get BioInvest's perspective on BioMarin's CEO


Latest Company News

Insider Trading Activity BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – CEO Sold ... Market Exclusive - 4 hours ago Jean Jacques Bienaime , CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reportedly Sold 5,000 shares of the company's stock at an average price of 94 for a total transaction amount of $470,000.00 SEC Form. BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105.00 at BMO Capital Markets - The Cerbat Gem Few Things investors Didn't Know About: BioMarin Pharmaceutical Inc. (BMRN ... - StockNewsJournal [...]
Fri, Apr 28, 2017 12:45:00 AM, Continue reading at the source
Trading Options: BioMarin Pharmaceutical Inc (NASDAQ:BMRN) : Covered Calls ... CML News - 8 hours ago While covered calls are one of the most commonly used option strategies, it turns out we need to be clever in how we treat earnings in order to maximize the strategy in BioMarin Pharmaceutical Inc (NASDAQ:BMRN) . Even further, if we don't do this ... [...]
Thu, Apr 27, 2017 9:11:00 PM, Continue reading at the source
FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease ... PR Newswire (press release) - 12 hours ago SAN RAFAEL, Calif., April 27, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. BioMarin Prices Orphan Drug at $702000, Promises Big Discounts - Bloomberg BioMarin Pharma (BMRN) Brineura Approved for Batten Disease - StreetInsider.com [...]
Thu, Apr 27, 2017 5:26:00 PM, Continue reading at the source
BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again? Zacks.com - 15 hours ago We expect BioMarin Pharmaceutical Inc. (BMRN - Free Report) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes. [...]
Thu, Apr 27, 2017 2:37:00 PM, Continue reading at the source
BioMarin Pharmaceutical Inc. (BMRN) Shouts Loudly With Its Technical Chart NY Stock News - Apr 25, 2017 The technicals for BioMarin Pharmaceutical Inc. (BMRN) have taken shape, and with them a comprehensive picture has emerged. [...]
Tue, Apr 25, 2017 7:30:00 PM, Continue reading at the source
BioMarin Races Towards Next Rare Disease Approval Seeking Alpha - Apr 25, 2017 BioMarin (NASDAQ: BMRN), a biotech focused on rare and ulra-rare genetic diseases, is coming up on an April 27 PDUFA date for Brineura (cerliponase alfa) for CLN2 disease, a rare neurodegenerative disease with no approved treatment. [...]
Tue, Apr 25, 2017 2:26:00 PM, Continue reading at the source
BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase ... PR Newswire (press release) - Apr 21, 2017 SAN RAFAEL, Calif., April 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has ... [...]
Fri, Apr 21, 2017 5:26:00 PM, Continue reading at the source
BioMarin to Host First Quarter 2017 Financial Results Conference Call and ... PR Newswire (press release) - Apr 20, 2017 SAN RAFAEL, Calif., April 20, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, ... BioMarin Pharmaceutical Inc. (BMRN) Moves Lower on Volume Spike for April 21 - Equities.com Stock Returns: BioMarin Pharmaceutical Inc (NASDAQ:BMRN) versus Tesaro Inc ... - CML News [...]
Thu, Apr 20, 2017 8:48:00 PM, Continue reading at the source
BioMarin Pharmaceutical (BMRN) Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 24, 2017 To remind you all, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin's financial performance, commercial products, and potential ... Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey - Benzinga [...]
Fri, Feb 24, 2017 5:10:00 AM, Continue reading at the source
Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Meanwhile, plenty of clinical-stage programs at Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) have been chugging along without much drama, but the stock is looking mighty expensive lately. [...]
Mon, Feb 20, 2017 1:41:00 PM, Continue reading at the source